3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Phase NA
1
Phase 4
1
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
90
Triple Negative Breast Neoplasms
18
Stomach Neoplasms
14
Inflammatory Breast Neoplasms
12
Esophageal Neoplasms
7
Lymphoma, Large B-Cell, Diffuse
5
Testicular Neoplasms
3
Pancreatic Neoplasms
3
Lymphoma
3
Adenocarcinoma Of Esophagus
3
Urinary Bladder Neoplasms
2
Sarcoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Ovarian Neoplasms
2
Neoplasms, Germ Cell and Embryonal
2
Neoplasms
2
Lymphoma, B-Cell, Marginal Zone
2
Carcinoma, Hepatocellular
2
Carcinoma, Adenoid Cystic
2
Breast Neoplasms, Male
2
pCR Rate
1
Women With Primary Breast Cancer
1
Upper Tract Urothelial Carcinoma
1
Unilateral HER2 Positive Breast Cancer
1
Thymoma
1
Testicular Germ Cell Tumor
1
Small Cell Lung Cancer Extensive Stage
1
Rare Tumour
1
Prostatic Neoplasms
1
Primary Breast Cancer
1
Interventions
Gemcitabine
12
Mitomycin
6
Docetaxel
4
Radiotherapy
3
BCG Vaccine
3
tislelizumab
2
erdafitinib
2
dodecyl maltoside
2
disitamab vedotin
2
toripalimab
1
pemigatinib
1
pembrolizumab
1
monalizumab
1
linrodostat
1
enzalutamide
1
durvalumab
1
bicalutamide
1
avelumab
1
Watchful Waiting
1
Sugars
1
Postoperative Period
1
Pentosan Sulfuric Polyester
1
Nonsteroidal Anti-Androgens
1
Nivolumab
1
Metformin
1
Imiquimod
1
Hyaluronic Acid
1
High-Intensity Interval Training
1
Gels
1
Epirubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Non-Muscle Invasive Bladder Neoplasms
×
Epirubicin
×
Clear all
NCT06227065
2024-01-26
POLO
University of Bern
Phase 2
Not yet recruiting
28 enrolled